search
Back to results

Acute Kidney Injury After Cardiac Surgery

Primary Purpose

Cardiac Surgical Procedures, Extracorporeal Circulation; Complications, Acute Kidney Injury

Status
Recruiting
Phase
Not Applicable
Locations
Sweden
Study Type
Interventional
Intervention
Colloid priming solution for ECC circuit
Standard priming solution for ECC circuit
Sponsored by
XVIVO Perfusion
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Cardiac Surgical Procedures focused on measuring Colloid priming solution, Cardiopulmonary bypass, Extracorporeal circulation, ECC, Acute Kidney Injury, AKI

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Has signed and dated the EC approved informed consent
  • Subject is ≥ 18 years of age
  • Requires elective or urgent (non-emergency) cardiac procedure requiring the use of ECC.
  • Preoperative "Acute kidney injury risk score" ≥30%, found at http://cardiacsurgeryleicester.com/our-research/acute-kidney-injury-risk-score-calculator/

Exclusion Criteria:

  • Unable to give informed consent
  • Known bleeding disorder
  • Known intolerance or contraindication to dextran
  • Acute Surgery (requires emergency cardiac procedure/surgery)
  • Currently using an antithrombotic medication which has not been discontinued per institution protocol
  • Malignancy; Surgery within 5 years or ongoing antitumoral treatment
  • Has ongoing sepsis or endocarditis
  • Requires pre-operative dialysis

Sites / Locations

  • Sahlgrenska University HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Colloid priming solution for ECC circuit

Standard priming solution for ECC circuit

Arm Description

Priming of ECC circuit with approximately 1200 mL PrimECC.

Priming of ECC circuit with approximately 1200 mL standard priming solution (crystalloid solution with or without mannitol addition as per routine of the participating clinic).

Outcomes

Primary Outcome Measures

Incidence of post-operative AKI
Incidence of postoperative AKI of any stage according to the KDIGO creatinine criteria (serum-creatinine increase ≥ 27 μmol/l within 48 hours or ≥ 50 % increase from baseline)

Secondary Outcome Measures

NAG excretion
NAG-excretion (U-NAG/U-creatinine)
eGFR
pre-operative (day before surgery) compared to the highest post-operative value Measured value of pre-operative eGFR compared to the highest post-operative value within 96 hours after ICU arrival, calculated using the CKD-EPI formula
Incidence of AKI
Incidence of AKI of different stages according to the KDIGO creatinine criteria
Hemolysis
Hemolysis measured as free hemoglobin (PfHb)
CNS injury markers
Measured concentrations of CNS injury markers Tau, NFL, NSE, and S100B
Myocardial injury markers
Measured concentrations of myocardial injury markers TnI or TnT. TnI or TnT is chosen according to institutional standard

Full Information

First Posted
January 17, 2020
Last Updated
April 21, 2022
Sponsor
XVIVO Perfusion
search

1. Study Identification

Unique Protocol Identification Number
NCT04293744
Brief Title
Acute Kidney Injury After Cardiac Surgery
Official Title
Acute Kidney Injury After Cardiac Surgery; A Prospective Randomized Study of Dextran Based and Crystalloid Priming Solutions (PRIMING II Trial)
Study Type
Interventional

2. Study Status

Record Verification Date
April 2022
Overall Recruitment Status
Recruiting
Study Start Date
September 4, 2020 (Actual)
Primary Completion Date
January 31, 2023 (Anticipated)
Study Completion Date
January 31, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
XVIVO Perfusion

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
PrimECC is a colloid priming solution for cardiopulmonary bypass/ extracorporeal circulation (ECC) based on Ringers Lactate, supplmeneted with Dextran 40 and Dextran 1. In a previous RCT comparing PrimECC with crystalloid priming fluid, patients in the PrimECC group experienced less hemolysis, less tubular cell injury and beneficial effect on the fluid balance. This study will investigate if, in a population at high risk of acute kidney injury (AKI), priming the ECC circuit with PrimECC instead of crystalloid solution will lead to a reduction of postoperative AKI. The hypothesis is that PrimECC, compared to crystalloid prime, will reduce postoperative AKI. The study is a Swedish multicenter, double-blinded, randomized, controlled clinical trial. The trial will include 366 patients aged ≥18 years, scheduled for cardiac surgery with cardiopulmonary bypass, with an "Acute kidney injury risk score" ≥30% according to Birnie et al. (2014). The primary outcome of the study is the incidence of postoperative AKI of any stage according to the KDIGO creatinine criteria (serum-creatinine increase ≥ 27 μmol/l within 48 h or ≥ 50 % increase from baseline) within 96 hours after arrival to the ICU. Secondary outcomes are between-group differences in hemolysis, tubular cell injury (NAG-excretion), estimated GFR, and incidence of AKI of different stages according to the KDIGO creatinine criteria. In addition, differences in CNS (Tau, NFL, NSE, and S100B) and cardiac (TNT/TNI) injury markers will be investigated.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cardiac Surgical Procedures, Extracorporeal Circulation; Complications, Acute Kidney Injury
Keywords
Colloid priming solution, Cardiopulmonary bypass, Extracorporeal circulation, ECC, Acute Kidney Injury, AKI

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
366 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Colloid priming solution for ECC circuit
Arm Type
Experimental
Arm Description
Priming of ECC circuit with approximately 1200 mL PrimECC.
Arm Title
Standard priming solution for ECC circuit
Arm Type
Active Comparator
Arm Description
Priming of ECC circuit with approximately 1200 mL standard priming solution (crystalloid solution with or without mannitol addition as per routine of the participating clinic).
Intervention Type
Device
Intervention Name(s)
Colloid priming solution for ECC circuit
Intervention Description
Prospective, multi-center, double-blinded, randomized, controlled clinical trial
Intervention Type
Device
Intervention Name(s)
Standard priming solution for ECC circuit
Intervention Description
Prospective, multi-center, double-blinded, randomized, controlled clinical trial
Primary Outcome Measure Information:
Title
Incidence of post-operative AKI
Description
Incidence of postoperative AKI of any stage according to the KDIGO creatinine criteria (serum-creatinine increase ≥ 27 μmol/l within 48 hours or ≥ 50 % increase from baseline)
Time Frame
Within 96 hours after ICU arrival
Secondary Outcome Measure Information:
Title
NAG excretion
Description
NAG-excretion (U-NAG/U-creatinine)
Time Frame
1 hour post initiation of ECC, at 1 hour after disconnection from ECC and 24 hours after disconnection from ECC.
Title
eGFR
Description
pre-operative (day before surgery) compared to the highest post-operative value Measured value of pre-operative eGFR compared to the highest post-operative value within 96 hours after ICU arrival, calculated using the CKD-EPI formula
Time Frame
Pre-operative and within 96 hours after ICU arrival
Title
Incidence of AKI
Description
Incidence of AKI of different stages according to the KDIGO creatinine criteria
Time Frame
Within 96 hours after ICU arrival
Title
Hemolysis
Description
Hemolysis measured as free hemoglobin (PfHb)
Time Frame
Pre-operative (after induction of anesthesia) and at 1 hour post initiation of ECC, 1 hour after disconnection from ECC and at 24 hours after disconnection from ECC.
Title
CNS injury markers
Description
Measured concentrations of CNS injury markers Tau, NFL, NSE, and S100B
Time Frame
Pre-operative (after induction of anesthesia), 1 hour after disconnection from ECC and at 24 hours after disconnection from ECC.
Title
Myocardial injury markers
Description
Measured concentrations of myocardial injury markers TnI or TnT. TnI or TnT is chosen according to institutional standard
Time Frame
Pre-operative (after induction of anesthesia) and at 1 hour after discontinuation of ECC and 24 hours after disconnection from ECC.
Other Pre-specified Outcome Measures:
Title
Post-operative bleeding
Description
Drain losses
Time Frame
The first 24 hours after disconnection from ECC
Title
Post-operative transfusions and use of hemostatic agents
Description
Total transfusions and/or use of erythrocytes, plasma, thrombocytes, hemostatic pharmaceuticals
Time Frame
The first 24 hours after disconnection from ECC

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Has signed and dated the EC approved informed consent Subject is ≥ 18 years of age Requires elective or urgent (non-emergency) cardiac procedure requiring the use of ECC. Preoperative "Acute kidney injury risk score" ≥30%, found at http://cardiacsurgeryleicester.com/our-research/acute-kidney-injury-risk-score-calculator/ Exclusion Criteria: Unable to give informed consent Known bleeding disorder Known intolerance or contraindication to dextran Acute Surgery (requires emergency cardiac procedure/surgery) Currently using an antithrombotic medication which has not been discontinued per institution protocol Malignancy; Surgery within 5 years or ongoing antitumoral treatment Has ongoing sepsis or endocarditis Requires pre-operative dialysis
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Kristina Welinder
Phone
+4676-1750562
Email
kristina.welinder@xvivogroup.com
First Name & Middle Initial & Last Name or Official Title & Degree
Sofia Jonhede
Phone
+46763286731
Email
sofia.jonhede@xvivogroup.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Lukas Lannemyr, MD,PhD
Organizational Affiliation
Sahlgrenska University Hospital, Sweden
Official's Role
Principal Investigator
Facility Information:
Facility Name
Sahlgrenska University Hospital
City
Gothenburg
State/Province
Västra Götalands Län
ZIP/Postal Code
41251
Country
Sweden
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lukas Lannemyr, MD Phd
First Name & Middle Initial & Last Name & Degree
Lukas Lannemyr, MD Phd

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
Individual participant data will not be shared with other researchers

Learn more about this trial

Acute Kidney Injury After Cardiac Surgery

We'll reach out to this number within 24 hrs